PD-1 antibody "new partner": fusion of IL-21 has greatly improved anti-tumor efficacy

png">

PD-1 inhibitors can restore the vitality of bioon.

The researchers observed that PD-1AB21 completely blocked the binding of PD-L1IgFc after binding to EG7 lymphoma cells expressing PD-1 and activated CD8+ T cells.

This indicates that PD-1AB21 can bind to PD-1 on activated T cells, blocking the interaction of PD-1 and PD-L1, while maintaining the biological activity of IL-21.

After in-depth exploration, the researchers found that PD-1Ab21 can target IL-21 to activated T cells, and compared to recombinant IL-21, it can more effectively induce activated CD8+ T cells to differentiate into TSCM cells (memory stem T cells).

TSCM cells have strong proliferation potential, long-term survival ability and the ability to generate all memory and effector T cell subsets after exposure to antigen.

Tumor-bearing mice showed an increase in the frequency of TSCM and a large number of tumor-specific memory T cells after PD-1AB21 treatment, and the anti- bioon.